Switching from intravenous to subcutaneous infliximab was generally feasible, safe, and well-accepted, leading to a low risk of relapse in most patients with inflammatory bowel disease, a new study indicates.
Switching from intravenous to subcutaneous infliximab was generally feasible, safe, and well-accepted, leading to a low risk of relapse in most patients with inflammatory bowel disease, a new study indicates.
Switching from intravenous to...